

July 25, 2022

Company name: Amvis Holdings, Inc.
Name of representative: Keiichi Shibahara, Representative Director and CEO
Securities code: 7071; Tokyo Stock Exchange Standard
Inquiries: Tetsuya Nakagawa, Director and CFO

Notification Regarding Revisions to Financial Results Forecasts

Amvis Holdings, Inc. (Chuo-ku, Tokyo; Representative Director and CEO: Keiichi Shibahara, hereinafter, the "Company") announces that, in light of recent operating performance and other factors, the Company has decided to revise the forecasts of consolidated financial results announced on November 11, 2021, when it announced the financial results for the fiscal year ended September 30, 2021. Details are as described below.

1. Revisions to Consolidated Financial Results Forecasts for the Fiscal Year Ending September 30, 2022 (October 1, 2021 to September 30, 2022)

	Net Sales	Operating Profit	Profit Attributable to Owners of Parent	Earnings per Share
	million yen	million yen	million yen	yen
Previous forecast (A)	21,682	4,965	3,301	68.00
Revised forecast (B)	22,487	5,800	3,975	81.87
Change (B-A)	805	834	673	—
Percentage change (%)	3.7	16.8	20.4	—
(Reference) Actual results of FY21	15,334	3,784	2,627	56.15

(Note) As of January 1, 2022, a 2-for-1 stock split has been implemented. Therefore, earnings per share are calculated as if it had been implemented at the beginning of the previous fiscal year.

2. Reasons for Revisions

Despite the negative impact due to the Omicron variant, utilization rates at both existing facilities and new facilities from Q1 to Q3 were higher than expected. In particular, the utilization rate at new facilities, mainly in the Tokyo metro area, has remained favorable. In addition, personnel expenses as a percentage of net sales were lower than expected by managing the personnel structure based on forecasts of utilization rates while maintaining enough personnel numbers of medical workers more than the number of patients. As of June 2022, the Company secured 2,179 medical workers for 2,092 patients, maintaining a robust medical system.

In light of the above situation, although the future impact of COVID-19 remains difficult to predict in some respects, the Company has revised upwardly its forecasts from the previously announced figures.

Note:

The forecasts above are based on the intent, beliefs and current expectations of the Company and its management with respect to the expected financial condition and results of operations of the Company. Actual performance and results may differ from those forecasts due to various factors.